ad

Laurus Labs Q2 Results 2025 Highlights: Net Profit Rises by 882.71% & Revenue Up 35.12% YoY

Click and Sign Up to Get Live Updates on Q2 Results 


24 Oct 20255:14 pm

Laurus Labs Q2 Results 2025 Highlights: Net Profit Rises by 882.71% & Revenue Up 35.12% YoY

Laurus Labs Q2 Results FY26: During Q2 FY26, Laurus Labs’ profit increased 882.17% YoY, while revenue increased by 35.12% YoY. The company posted robust numbers, with Q2 PAT at ₹194.97 crores and revenue at ₹1,653.47 crores. Laurus Labs showed its Q2 results on 23rd October 2025.  

Laurus Labs Q2 Results FY26: Extracts of FY25 & FY26

ParticularsConsolidated FiguresStandalone Figures
30th Sep 202530 Sept 202430th Sept 202530th Sept 2024
Revenue from Operations₹1,653.47₹1,223.70₹1,566.50₹1,184.85
Profit Before Tax (PBT)₹430.22₹182.93₹418.11₹193.72
Profit After Tax (PAT)₹194.97₹19.84₹215.67₹42.44

Laurus Labs Q2 Results FY26 Highlights (Q2 FY26 vs FY25)

  • Laurus Labs clocked Q2 FY26 consolidated revenue of ₹1,653.47 crores vs ₹1,223.70 crores. 
  • On the profit front, Laurus Labs earned a consolidated PAT of ₹194.97 crore in Q2 FY26. During FY25, the company’s PAT stood at ₹19.84 crore.
  • According to the consolidated figures, Laurus Labs’ quarterly PAT increased by 882.17% YoY, while revenue increased by 35.12%.
  • Laurus Labs clocked Q2 FY26 standalone revenue of ₹1,556.50 crores vs ₹1,184.85 crores. 
  • On the profit front, Laurus Labs earned a standalone PAT of ₹215.67 crore in Q2 FY26. During FY25, the company’s PAT stood at ₹42.44 crore.
  • According to the standalone figures, Laurus Labs’ quarterly PAT increased by 408.18% YoY, while revenue increased by 32.22%.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

About Laurus Labs Limited

Laurus Labs was established in 2005, with its headquarters in Hyderabad. Laurus Labs is an integrated pharmaceutical and biotechnology company. The company operates across four main business areas, including Active Pharmaceutical Ingredients (APIs), which includes a leadership position in anti-retrovirals (ARVs), Hepatitis, and oncology. The company has a global presence and focuses on providing affordable and high-quality pharmaceutical solutions through its research-driven approach and compliant manufacturing facilities.   

Laurus Labs Share Price Performance

On the opening bell on 24th October 2025, Laurus Labs shares opened at ₹939.75 per share. However, the initial gains have since eroded, and Laurus Labs shares are trading at ₹923.35 per share, below the opening price.    

Considering the long-term achievements, Laurus Labs shares have yielded close to 43.04% returns in the past 6 months, and 1-year returns stand at 106.43%. Over the maximum timeframe, Laurus Labs shares delivered a 873.51% return to investors. 

What Analysts Expect Post Q2 Results?

Following robust Q2 results from Laurus Labs, analysts expect its share price to rise. According to analysts, Laurus Labs’ share price could reach ₹998.40 per share in the coming year and, in a downturn, could hit ₹915.30 per share. However, one must ignore stock market volatility and invest in Laurus Labs’ shares after thorough research. 

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Recent Articles

Nestle Q2 Results FY26: Q2 PAT Falls 17.38% to ₹743.17 Crore; Revenue Up 10.57% YoY

Inspira Enterprise India IPO Details: Everything You Should Know about 

Swaraj Engines Q2 Results FY26: Q2 PAT Rises 8.88% to ₹49 Crore; Revenue Up 8.62% YoY

HDB Financial Q2 Results FY26: Q2 PAT Falls 1.5% to ₹581 Crore; Revenue Up 13.42% YoY

BEL Gears Up for Q2 Reveal on 4th November; Check Key Expectations Here

Paytm Gears Up for Q2 Reveal on 4th November; Check Key Expectations Here

Blue Dart Gears Up for Q2 Reveal on 28th October; Check Key Expectations Here

Recent Articles

Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.

Reviews

user-review-1
user-review-2
user-review-3
user-review-4
user-review-5

RESEARCH ANALYST

Get SEBI Registered
advice on the stocks
trending today.

Get 3 FREE Trade Ideas

+91
Google for Startups Accelerator 2024
Trusted by 70 lakh+ Indians
Awarded No. 1 by Economic times